September 22, 2017 – FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Previously Treated Patients with Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Whose Tumors Express PD-L1

Today, Merck announced that the FDA has approved the anti-PD-1 therapy, Keytruda (pembrolizumab) for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1. This makes Keytruda the first PD-1 checkpoint inhibitor approved in the United States for previously treated gastric or GEJ cancer.
Treatment Options
View Full Article
Related Videos